Antibody Drug Conjugates: windows of opportunity
Drug Target Review
JULY 4, 2023
Working in the CRO and CDMO environment she has led projects for customers across the globe, helping them to achieve their goals in clinical trials and low volume commercial manufacture. Petra holds a D.Phil in synthetic organic chemistry and am MBA from Imperial College London. 2022 Nov 14 [cited 2023 Apr 6];40(11):1255–63.
Let's personalize your content